


PRODUCT INFORMATION



BDP9066

Item No. 26264

CAS Registry No.: 2226507-04-4
Formal Name: (6S)-8-[3-(4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1,8-diazaspiro[5.5]undecane
MF: C₂₀H₂₄N₆
FW: 348.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BDP9066 is supplied as a solid. A stock solution may be made by dissolving the BDP9066 in the solvent of choice, which should be purged with an inert gas. BDP9066 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

BDP9066 is slightly soluble (0.1-1 mg/ml) in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

BDP9066 is an inhibitor of Cdc42-binding kinase α (MRCK α) and MRCK β (K_i s = 0.0136 and 0.0233 nM, respectively).¹ It is selective for MRCK α and MRCK β over Rho-associated kinase 1 (ROCK1) and ROCK2 (K_i s = 18.4 and 5.38 nM, respectively) and a panel of 115 additional kinases at 1 μ M. BDP9066 has antiproliferative activity against a panel of 757 cancer cell lines (EC_{50} s = <10 μ M). It inhibits the phosphorylation of myosin light-chain 2 (MLC2) in SCC-12 squamous cell carcinoma cells (EC_{50} = 64 nM) and inhibits the motility of the same cells. BDP9066 (25 μ g/animal) decreases average papilloma volume in a mouse two-stage model of skin carcinogenesis initiated by 7,12-dimethylbenz[a]anthracene (DMBA; Item No. 30383) and promoted by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014).

Reference

1. Unbekandt, M., Belshaw, S., Bower, J., *et al.* Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer. *Cancer Res.* **78(8)**, 2096-2114 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM